A Therapeutic Equivalence Study in Subjects With Primary Open Angle Glaucoma or Ocular Hypertension

NCT ID: NCT05022004

Last Updated: 2024-01-18

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE3

Total Enrollment

599 participants

Study Classification

INTERVENTIONAL

Study Start Date

2021-12-20

Study Completion Date

2023-01-06

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This is a randomized, Investigator-masked, multi-center, parallel group, therapeutic equivalence study with clinical endpoint.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Primary Open Angle Glaucoma Ocular Hypertension

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

TRIPLE

Participants Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

BRIN-20-01

Group Type EXPERIMENTAL

Brinzolamide ophthalmic suspension

Intervention Type DRUG

dose: one drop of study medication; frequency: three times a day; route of administration: Topical ocular administration; duration of therapy: 6 weeks

Azopt®

Group Type ACTIVE_COMPARATOR

Azopt®

Intervention Type DRUG

dose: one drop of study medication; frequency: three times a day; route of administration: Topical ocular administration; duration of therapy: 6 weeks

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Brinzolamide ophthalmic suspension

dose: one drop of study medication; frequency: three times a day; route of administration: Topical ocular administration; duration of therapy: 6 weeks

Intervention Type DRUG

Azopt®

dose: one drop of study medication; frequency: three times a day; route of administration: Topical ocular administration; duration of therapy: 6 weeks

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Male or nonpregnant female aged 18 years or older with chronic open angle glaucoma or ocular hypertension in both eyes.
* Provide signed and dated informed consent in accordance with good clinical practice and local legislation prior to any study procedure.
* Be able and willing to follow study instructions and complete all required visits.
* Subject requires treatment of both eyes and is able to discontinue use of all ocular hypotensive medication(s) or switch ocular hypotensive medications and undergo appropriate washout period.

Exclusion Criteria

* Subjects with angle closure glaucoma
* Females who are pregnant, breast feeding, or planning a pregnancy.
* Females of childbearing potential who do not agree to utilize an adequate form of contraception.
* Current, or past history of, severe hepatic or renal impairment
* Current, or history within 2 months prior to baseline of, significant ocular disease
* Functionally significant visual field loss
* Contraindication to brinzolamide or sulfonamide therapy or known hypersensitivity to any component of brinzolamide or sulfonamide therapy
* Subjects currently in another clinical trial
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Sun Pharmaceutical Industries Limited

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

GMC, Srikakulam

Srikakulam, Andhra Pradesh, India

Site Status

Dr. RSPR Govt Regional Eye Hospital; Vishakapatnam

Visakhapatnam, Andhra Pradesh, India

Site Status

Rising Retina Clinic

Ahmedabad, Gujarat, India

Site Status

Bhavna Super speciality Eye care

Surat, Gujarat, India

Site Status

Dr. BR Ambedkar Medical College and hospital

Bangalore, Karnataka, India

Site Status

Bhagwan Mahaveer Jain Hospital

Bangalore, Karnataka, India

Site Status

KLE's Dr. Prabhakar Kore Hospital & Medical Research Center

Belagavi, Karnataka, India

Site Status

K R Hospital, Mysore Medical College and Research Institute

Mysuru, Karnataka, India

Site Status

Shanti Saroj Netralay

Miraj, Maharashtra, India

Site Status

Omkar Eye Care Center

Mumbai, Maharashtra, India

Site Status

Acharya Vinoba Bhave Rural Hospital, Jawaharlal Nehru Medical College, Datta Meghe Institute of Medical Sciences

Wardha, Maharashtra, India

Site Status

Sankara Nethralaya

Chennai, Tamil Nadu, India

Site Status

Dr Agarwal's Eye Hospital

Tirunelveli, Tamil Nadu, India

Site Status

Heritage Institute of Medical Sciences

Varanasi, Uttar Pradesh, India

Site Status

Institute of Human Brain of the Russian Academy of Science, 197376, Academ. Pavlov street 12 AP, StPetersburg, Russia

Saint Petersberg, Sankt-Peterburg, Russia

Site Status

Republican clinical ophthalmological hospital of Ministry of Health of Republic of Tatarstan named after E.V. Adamyuk

Kazan', Tatarstan Republic, Russia

Site Status

Federal State Autonomous Institution "Interdistrict Scientific and Technical Complex "Eye Microsurgery" named after Academician S.N. Fedorov" of the Ministry of Healthcare of the Russian Federation

Cheboksary, , Russia

Site Status

Healthcare Organization "Eye Center", Limited Liability Company

Chelyabinsk, , Russia

Site Status

Federal State Autonomous Institution "Interdistrict Scientific and Technical Complex "Eye Microsurgery" named after Academician S.N. Fedorov" of the Ministry of Healthcare of the Russian Federation

Irkutsk, , Russia

Site Status

Ivanovo Regional Clinical Hospital

Ivanovo, , Russia

Site Status

"Eye Microsurgery" n a Academician S.N. Fedorov"

Kaluga, , Russia

Site Status

Federal State Autonomous Institution "Interdistrict Scientific and Technical Complex "Eye Microsurgery" named after Academician S.N. Fedorov" of the Ministry of Healthcare of the Russian Federation

Khabarovsk, , Russia

Site Status

"Angris", Limited Liability Company

Moscow, , Russia

Site Status

Moscow Medical university n.a. Sechenov

Moscow, , Russia

Site Status

Federal State Autonomous Institution "Interdistrict Scientific and Technical Complex "Eye Microsurgery" named after Academician S.N. Fedorov" of the Ministry of Healthcare of the Russian Federation

Moscow, , Russia

Site Status

Federal State Budgetary Educational Institution of Higher Education "Moscow State University of Medicine and Dentistry named after A.I. Evdokimov" of the Ministry of Healthcare of the Russian Federation

Moscow, , Russia

Site Status

"Moscow Regional Clinical Research Institute named after M.F. Vladimirsky"

Moscow, , Russia

Site Status

Federal budgetary healthcare institution Privolzhsky district medical center FMBA of Russia.

Nizhny Novgorod, , Russia

Site Status

Federal State Autonomous Institution "Interdistrict Scientific and Technical Complex "Eye Microsurgery" named after Academician S.N. Fedorov" of the Ministry of Healthcare of the Russian Federation

Novosibirsk, , Russia

Site Status

Budgetary Healthcare Institution of the Omsk Region "Clinical Eye Hospital named after V.P. Vykhodtsev

Omsk, , Russia

Site Status

Federal State Autonomous Institution "Interdistrict Scientific and Technical Complex "Eye Microsurgery" named after Academician S.N. Fedorov" of the Ministry of Healthcare of the Russian Federation

Saint Petersburg, , Russia

Site Status

"X7 Clinical Research", Limited Liability Company

Saint Petersburg, , Russia

Site Status

Feral State Budgetary Healthcare Institution "Clinical Hospital No. 122 named after L.G. Sokolov of the Federal Medical and Biological Agency"

Saint Petersburg, , Russia

Site Status

Samara medical university

Samara, , Russia

Site Status

Nongovernmental Healthcare Institution "Clinical Hospital "RZhD [Russian Railways]-

Saratov, , Russia

Site Status

State Budgetary Institution "Ufa Research Institute of Eye Diseases of the Academy of Sciences of the Republic of Bashkortostan

Ufa, , Russia

Site Status

ZAO "Optimedservice"

Ufa, , Russia

Site Status

Ulyanovsk ophthalmology clinical "Prozrenie"

Ulyanovsk, , Russia

Site Status

Federal Budgetary Healthcare Institution "Volga Region Medical Centre" of the Federal Medical and Biological Agency

Veliky Novgorod, , Russia

Site Status

Federal State Autonomous Institution "Interdistrict Scientific and Technical Complex "Eye Microsurgery" named after Academician S.N. Fedorov" of the Ministry of Healthcare of the Russian Federation

Volgograd, , Russia

Site Status

Countries

Review the countries where the study has at least one active or historical site.

India Russia

Provided Documents

Download supplemental materials such as informed consent forms, study protocols, or participant manuals.

Document Type: Study Protocol

View Document

Document Type: Statistical Analysis Plan

View Document

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

BRIN-20-01

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.